In some experimental and clinical trials, Epratuzumab, a chimeric monoclonal antibody (mAb) binding to the C2-set Ig domain of CD22, was demonstrated to slow the progressions of SLE by inhibiting B cell activation and autoantibody production [5]. This evidence concerns the gene CD22 and systemic lupus erythematosus.